Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry
NCT02443428 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77
Last updated 2016-04-15
Summary
The purpose of this prospective observational registry is to monitor safety of eribulin in routine clinical practice. Additionally, this study will also assess the effectiveness of eribulin in real-life settings.
Conditions
Sponsors & Collaborators
-
Eisai Limited
lead INDUSTRY
Principal Investigators
-
Hartmut Kristeleit · Guy's Hospital, Great Maze Pond
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-08-31
- Primary Completion
- 2015-10-31
- Completion
- 2015-10-31
Countries
- Denmark
- Ireland
- United Kingdom
Study Locations
More Related Trials
-
Halaven Patient Registry (Metastatic Breast Cancer, MBC)
NCT03245112 ·Status: UNKNOWN
-
Loreline Study: Characterization of Long Responders Under Eribuline
NCT03771183 ·Status: COMPLETED
-
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
NCT01439282 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
NCT06341894 ·Status: RECRUITING ·Phase: PHASE2
-
Extended Treatment in Metastatic Breast Cancer With Eribulin
NCT02769364 ·Status: COMPLETED
-
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
NCT01463891 ·Status: COMPLETED
-
Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer
NCT05033769 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
NCT03437083 ·Status: COMPLETED
-
A Study of E7389 in Advanced/Metastatic Breast Cancer Patients
NCT00097721 ·Status: COMPLETED ·Phase: PHASE2
-
Retroprospective Real Life Observatory of Eribulin
NCT02393287 ·Status: COMPLETED
-
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
NCT04683445 ·Status: UNKNOWN
-
Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.
NCT02371174 ·Status: COMPLETED
-
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
NCT01795586 ·Status: COMPLETED ·Phase: PHASE1
-
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
NCT01554371 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer
NCT03583944 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
NCT00371345 ·Status: COMPLETED ·Phase: PHASE2
-
PhII ICb With/Without Erbitux in MBC Pts
NCT00248287 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Confirmation Study of Eribulin in Combination With Capecitabine
NCT01323530 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
NCT03430518 ·Status: COMPLETED ·Phase: PHASE1
-
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
NCT02864030 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
NCT02623972 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
NCT04288089 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes
NCT03412955 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
NCT00879086 ·Status: COMPLETED ·Phase: PHASE2
-
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
NCT03822468 ·Status: COMPLETED ·Phase: PHASE2